Background:Staphylococcus aureus bloodstream infection (SA-BSI) causes morbidity and mortality. We established a management protocol for patients with SA-BSI aimed at improving quality of care and patient outcomes. Methods: A retrospective pre–post intervention study was conducted at Maharaj Nakorn Chiang Mai Hospital from 1 October 2019 to 30 September 2020 in the pre-intervention period and from 1 November 2020 to 31 October 2021 in the post-intervention period. Results: Of the 169 patients enrolled, 88 were in the pre-intervention and 81 were in the post-intervention periods. There were similar demographic characteristics between the two periods. In the post-intervention period, evaluations for metastatic infections were performed more frequently, e.g., echocardiography (70.5% vs. 91.4%, p = 0.001). The appropriateness of antibiotic prescription was higher in the post-intervention period (42% vs. 81.5%, p < 0.001). The factors associated with the appropriateness of antibiotic prescription were ID consultation (OR 15.5; 95% CI = 5.9–40.8, p < 0.001), being in the post-intervention period (OR 9.4; 95% CI: 3.5–25.1, p < 0.001), and thorough investigations for metastatic infection foci (OR 7.2; 95% CI 2.1–25.2, p = 0.002). However, the 90-day mortality was not different (34.1% and 27.2% in the pre- and post-intervention periods, respectively). The factors associated with mortality from the multivariate analysis were the presence of alteration of consciousness (OR 11.24; 95% CI: 3.96–31.92, p < 0.001), having a malignancy (OR 6.64; 95% CI: 1.83–24.00, p = 0.004), hypoalbuminemia (OR 5.23; 95% CI: 1.71–16.02, p = 0.004), and having a respiratory tract infection (OR 5.07; 95% CI: 1.53–16.84, p = 0.008). Source control was the only factor that reduced the risk of death (OR 0.08; 95% CI: 0.01–0.53, p = 0.009). Conclusion: One-third of patients died. Hospital-wide protocol implementation significantly improved the quality of care. However, the mortality rate did not decrease.
Weight gain is a recognized complication of modern antiretroviral therapy, especially with dolutegravir-based regimens associated with adverse metabolic outcomes. Lifestyle modification is first-line management. Randomized controlled trial evidence remains limited. Our study aimed to evaluate the efficacy of a six-month weight reduction intervention compared with standard treatment. A six-month, open-label, RCT was conducted in PLWH who had gained ≥ 5% of body weight since starting dolutegravir. Participants were randomized 1:1 to either a structured weight reduction program or standard care. The primary outcome was the percentage change in body weight from baseline to six months. Predictors of weight reduction were assessed using multivariable linear regression. Fifty-eight participants completed the study. At six months, the intervention group lost a mean of − 1.15 kg (–1.47%) compared with a gain of + 0.31 kg (+ 0.34%) in the standard care group, yielding a between-group difference of − 1.46 kg (p = 0.039). In multivariable analysis, assignment to the intervention group was the only significant predictor of weight reduction (β = − 1.81; p = 0.049). A six-month structured lifestyle intervention resulted in modest but statistically significant weight reduction among PLWH with weight gain after DTG initiation. However, this weight reduction did not improve metabolic outcomes. Trial registration TCTR20240818003 (18 August 2024).
Here we present a case of atypical manifestation of Sporothrix schenkii infection where the patient complained solely of lymphadenopathy without any prior noticeable skin lesions. A Thai female who had been working in Malaysia presented to a healthcare facility with a three-month history of progressively larger and more painful lymphadenopathy at her right chin.